Northern California Hematology Oncology Conference: A Tumor Board Case-Based Approach to the Latest Breakthroughs

Sacramento, CA US
January 10, 2025 to January 11, 2025

The Northern California Hematology Oncology Conference: A Tumor Board Case-Based Approach to the Latest Breakthroughs is a CME-accredited, in-person hematology oncology conference designed to improve the care of cancer patients by educating clinicians involved in cancer care.

The expert faculty will present a comprehensive overview of recent updates in hematology and oncology. The program will feature in-depth discussions and analyses of the latest scientific discoveries and advancements. Faculty will contextualize these findings within clinical practice and explore their potential to alter current standards of care. This conference is designed for physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals, providing them with the latest updates in the field. Emphasizing a multidisciplinary approach, it will showcase the integration of new advancements into patient-centered care.

Target Audience

  • Hematologists, Oncologists

  • Surgeons

  • Radiation Oncologists

  • Physician Assistants/Nurse Practitioners

  • Pharmacists

  • Nurses

Organizing Committee

Conference Director:

Binay Shah, MD, MHA Binaytara Foundation

Conference Chair:

Deepti Behl, MD - Sutter Health

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  1. Review recent updates and discuss their applications in clinical settings.    
  2. Choose new therapeutic options for treating benign and malignant hematologic disorders and solid tumors, understanding appropriate indications and contraindications to these therapeutic approaches.
  3. Discuss the study design and primary endpoints of recently reported and ongoing trials that have influenced the changes in the standards of care in hematology and oncology.
  4. Integrate evolving diagnostic, prognostic, and therapeutic approaches to managing hematologic disorders and oncology patients.
  5. Individualize management of patients based on emerging data from clinical trials and evolving expert guidelines.

Hotel Room Reservation

A limited number of guestrooms are reserved at the Double Tree Sacramento for the participants of this meeting at a discounted rate of $149 per night. The room rate does not include any additional fees or applicable taxes.

CUTOFF - Friday, December 20, 2024

Parking

Guests will receive discounted hotel parking at $5 per day

Course summary
Available credit: 
  • 8.25 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.25 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.25 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.25 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.25 Contact Hours.
Course opens: 
08/07/2024
Course expires: 
04/07/2025
Event starts: 
01/10/2025 - 4:00pm PST
Event ends: 
01/11/2025 - 4:30pm PST
Cost:
$150.00

DAY 1 - FRIDAY, JANUARY 10th, 2025

All times are listed in Pacific Time (PT)

02:00 PM – 03:00 PM  Registration, Networking, & Exhibits


03:00 PM – 03:15 PM  Welcome & Opening Remarks


03:15 PM – 04:45 PM  Session 1: Hematologic Malignancies: Case-Based Discussion

Session Chair: Rajesh Behl, MD

03:15 PM – 03:35 PM  MDS/Acute Leukemia - Brian Andrew Jonas, MD, PhD, FACP

03:35 PM – 03:55 PM  Lymphoma/CLL - Aaron Goodman, MD

03:55 PM – 04:15 PM  Multiple Myeloma - Alfred Chung, MD

04:15 PM - 04:45 PM  Panel Discussion


04:45 PM – 05:30 PM  Session 2: Changing Landscapes in Oncology - Liquid Biopsy

04:45 PM - 05:15 PM  Keynote Speech: Updates in Liquid Biopsy - Matthew Gubens, MD, MS, FASCO

05:15 PM - 05:30 PM  Q&A Session


05:30 PM – 06:30 PM  Reception, Networking, & Exhibits 


DAY 2 - SATURDAY, JANUARY 11th, 2025

07:00 AM – 08:00 AM  Registration, Breakfast & Exhibits


08:00 AM – 08:05 AM  Welcome

08:05 AM – 08:25 AM  Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD


08:25 AM –  09:40 AM Session 3: Thoracic Oncology: Case-Based Discussion

Session Chair: Hubert Pan, MD & Vijay Suhag, MD

08:25 AM – 08:45 AM  Early-Stage Lung Cancer - Tianhong Li, MD, PhD

08:45 AM – 09:05 AM  Advanced Lung Cancer - Rafael Santana-Davila, MD

09:05 AM – 09:25 AM  Small Cell Lung Cancer - Hatim Husain, MD

09:25 AM - 09:40 AM  Panel Discussion


09:40 AM – 10:00 AM Break & Exhibits


10:00 AM – 11:30 AM  Session 4: Genitourinary Cancer: Case-Based Discussion

Session Chair: Seth Rosenthal, MD, FACR, FASTRO

10:00 AM – 10:20 AM  Kidney Cancer - Mamta Parikh, MD, MS

10:20 AM – 10:40 AM  Prostate Cancer - 

10:40 AM – 11:00 AM  Bladder Cancer - Nitin Rohatgi, MD

11:00 AM - 11:30 AM  Panel Discussion


11:30 AM – 12:30 PM  Session 5: Challenging Cases 

Session Chair: Yelena Krijanovski, MD

11:30 AM – 11:45 AM  Melanoma - Kevin Kim, MD

11:45 AM – 12:00 PM  Sarcoma - Varun Monga, MBBS

12:00 PM – 12:15 PM  Head and Neck Cancer - Mohammad Hararah, MD, MPH

12:15 PM – 12:30 PM  Panel Discussion


12:30 PM – 01:30 PM  Lunch & Exhibits


01:30 PM – 02:30 PM  Session 6: Metastatic Breast Cancer: Case-Based Discussion

Session Chair: Sareena Malhi, MD

01:30 PM – 01:50 PM  Metastatic Breast Cancer 1 (Hormone Receptor Positive) - Kristie Bobolis, MD

01:50 PM – 02:10 PM  Metastatic Breast Cancer 2 (HER2+ and Triple-Negative Breast Cancer) - 

02:10 PM - 02:30 PM  Panel Discussion


02:30 PM – 03:30 PM  Session 7: GI Cancer: Case-Based Discussion

Session Chair: Dron Gauchan, MD & Jasdeepa Nagi, MD

02:30 PM – 02:50 PM  Upper GI Malignancies - Daneng Li, MD

02:50 PM – 03:10 PM  Lower GI Malignancies - Thorvardur Halfdanarson, MD

03:10 PM - 03:30 PM  Panel Discussion


03:30 PM  Adjourn

Double Tree Sacramento
2001 Point W Way
Sacramento, CA 95815
United States

Hotel Room Reservation

A limited number of guestrooms are reserved at the Double Tree Sacramento for the participants of this meeting at a discounted rate of $149 per night. The room rate does not include any additional fees or applicable taxes.

CUTOFF - Friday, December 20, 2024

Parking

Guests will receive discounted hotel parking at $5 per day

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Course Director(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Conference Chair(s)

DEEPTI BEHL, M.D.

has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with boehringer;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with AZ;.
has a financial relationship (Professional Services) with janssen;.
Session Chair(s)

Dron Gauchan

has no relevant financial relationships to disclose at this time.

Sareena Malhi

has no relevant financial relationships to disclose at this time.

Hubert Pan, MD

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

Matthew Gubens

has a financial relationship (Independent contractor) with Surface;.
has a financial relationship (Independent contractor) with Invitae;.
has a financial relationship (Independent contractor) with Cardinal Health;.
has a financial relationship (Independent contractor) with Sanofi;.
has a financial relationship (Independent contractor) with Gilead;.
has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Independent contractor) with Guardant;.
has a financial relationship (Independent contractor) with Atreca;.
has a financial relationship (Independent contractor) with Merus;.
has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Independent contractor) with AnHeart;.
has a financial relationship (Independent contractor) with Johnson and Johnson;.
has a financial relationship (Independent contractor) with Genzyme;.
Case Presenter(s)

Alfred Chung, Assistant Professor

has a financial relationship (Financial Support) with Janssen;.
has a financial relationship (Financial Support) with Cellectis;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Financial Support) with Caelum Biosciences;.
has a financial relationship (Travel) with Janssen;.
has a financial relationship (Financial Support) with Carsgen;.
has a financial relationship (Financial Support) with Bristol Myers Squibb;.
has a financial relationship (Financial Support) with Abbvie;.
has a financial relationship (Financial Support) with Merck;.

Tianhong Li, M.D., Ph.D.

has a financial relationship (Grant Or Contract) with Chugai Pharma;.
has a financial relationship (Grant Or Contract) with LabyRx Immuno-Oncology;.
has a financial relationship (Grant Or Contract) with RasCal Therapeutics;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Grant Or Contract) with Jounce Therapeutics;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Other) with BMS;.
has a financial relationship (Grant Or Contract) with Astellas;.
has a financial relationship (Grant Or Contract) with Genentech/LaRoche;.
has a financial relationship (Grant Or Contract) with OncoC4/BioNTech;.
has a financial relationship (Grant Or Contract) with Xilio Therapeutics;.
has a financial relationship (Grant Or Contract) with AbbVie;.
has a financial relationship (Grant Or Contract) with Duality Biologics;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Tempus;.

Varun Monga

has a financial relationship (Grant Or Contract) with Cogent Biosciences ;.
has a financial relationship (Grant Or Contract) with Amgen;.
has a financial relationship (Grant Or Contract) with Oblato Therapeutics;.
has a financial relationship (Grant Or Contract) with Orbus Therapetuics ;.
has a financial relationship (Grant Or Contract) with Prelude Therapeutics;.

Mamta Parikh, MD,MS

has a financial relationship (Other) with Gilead;.
has a financial relationship (Other) with Pfizer;.
has a financial relationship (Other) with Karyopharm;.
has a financial relationship (Other) with Sanofi Aventis;.
has a financial relationship (Other) with Bristol Myers Squibb;.

Nitin Rohatgi

has a financial relationship (Professional Services) with Lilly;.
has a financial relationship (Professional Services) with Stemline;.
has a financial relationship (Professional Services) with Astra Zeneca;.
has a financial relationship (Professional Services) with Astellas;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Gilead;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with Natera;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with Pfizer;.

Rafael Santana-Davila, MD

has a financial relationship (Professional Services) with Amgen;.
has a financial relationship (Professional Services) with Aztra-Zeneca;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with Astellas Pharma;.
has a financial relationship (Professional Services) with Mirati Therapeutics;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Abbvie;.
has a financial relationship (Grant Or Contract) with Monte Rosa Therapeutics;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Grant Or Contract) with Isa Pharmaceuticals;.
has a financial relationship (Grant Or Contract) with Daiichi Sankyo;.
has a financial relationship (Grant Or Contract) with Alpine Immune Sciences;.
has a financial relationship (Professional Services) with Catalyst Pharmaceuticals;.
has a financial relationship (Grant Or Contract) with Beyond Spring Pharmaceuticals;.
has a financial relationship (Grant Or Contract) with ALX Oncology ;.
has a financial relationship (Grant Or Contract) with Jounce Therapeutics;.

Acknowledgement of Commercial Support

This activity is supported with an Independent Medical Education Grant from Janssen Biotech, Inc.

Available Credit

  • 8.25 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.25 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.25 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.25 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.25 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$150.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.